STUDY OF OBLIMERSEN (GENASENSETM, G3139) IN ADVANCED MALIGNANCIES

Oblimersen（GENASENSETM，G3139）治疗晚期恶性肿瘤的研究

• 批准号: 7375227
• 负责人: BRANIMIR I SIKIC
• 金额: $ 1.11万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375227
• 关键词: STUDY; OBLIMERSEN; GENASENSETM; G3139; ADVANCED

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this protocol is to develop a novel therapy for cancer, by combining a cytotoxic chemotherapy combination with a new inhibitor of apoptosis. The rationale for the study is several fold. The cytotoxic agent Gemcitabine has substantial activity against several cancers. Oblimersen is an antisense inhibitor of bcl-2 and has been shown to produce growth inhibition and shrinkage in some human tumors as a single agent.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。该方案的总体目标是通过将细胞毒性化疗组合与新的细胞凋亡抑制剂相结合来开发一种新的癌症疗法。这项研究的理由有几个方面。细胞毒性剂吉西他滨对几种癌症具有显著的活性。Oblimersen是bcl-2的反义抑制剂，并且已经显示作为单一药剂在一些人类肿瘤中产生生长抑制和收缩。